Actively Recruiting
The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D)
Led by Research Unit for General Practice in Aalborg · Updated on 2025-08-17
600
Participants Needed
1
Research Sites
124 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this randomised controlled trial is to identify the optimal treatment duration with phenoxymethylpenicillin for community-acquired pneumonia diagnosed in general practice. Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics. Consenting patients who meet all the eligibility criteria will be randomised (1:1:1:1:1) to either three, four, five, six or seven days of treatment with phenoxymethylpenicillin 1.2 MIE four times daily.
CONDITIONS
Official Title
The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Presenting in general practice with symptoms of an acute lower respiratory tract infection lasting 21 days or less
- Symptoms include cough plus at least one of the following: shortness of breath, sputum production, wheezing, chest discomfort, or fever
- General practitioner considers antibiotic treatment relevant
You will not qualify if you...
- Need for immediate hospitalisation at diagnosis
- Known allergy to beta-lactam antibiotics
- Any coinfection requiring antibiotic treatment
- Use of systemic antibiotics or antivirals within the last month
- Pre-existing lung diseases such as chronic obstructive pulmonary disease, bronchiectasis, asthma, or lung cancer
- Known immunosuppression (long-term corticosteroids, chemotherapy, or immune disorders)
- Pregnant or lactating
- Unable to consent or deemed unsuitable for participation by healthcare professional
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Research Unit for General Practice Aalborg
Gistrup, Denmark, 9260
Actively Recruiting
Research Team
E
Eskild Johansen, MD, Ph.d.-student
CONTACT
M
Malene Plejdrup Hansen, MD, Associate Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here